Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

← catalyst calendar

NCT05292859

Sponsored by Alaunos Therapeutics (industry) · TCRT — their whole pipeline →.

Phase

—

Status

Completed

Study type

Observational

Enrollment

7actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-03-01

actual

When the study began enrolling

Primary completion

2025-05-30

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-05-30

actual

The whole study's end, after follow-up

First posted

2022-03-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-07-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Gynecologic Cancer
Colorectal Cancer
Pancreatic Cancer
Non-small Cell Lung Cancer
Cholangiocarcinoma
Ovarian Cancer
Ovary Neoplasm
Squamous Cell Lung Cancer
Adenocarcinoma of Lung
Adenosquamous Cell Lung Cancer

Intervention

Biological: Neoantigen specific TCR-T cell drug product

Primary outcomes

what the primary-completion date above is the date OF

To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells

measured Up to 2 years post TCR-T cell drug product infusion

To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells

measured Up to 15 years post TCR-T cell drug product infusion

Permalink · TCRT's whole pipeline · Catalyst calendar · Every registered study · What changed